Genedrive PLC PHE National Framework Agreement (8068V)
April 19 2021 - 1:00AM
UK Regulatory
TIDMGDR
RNS Number : 8068V
Genedrive PLC
19 April 2021
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN
REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE
COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION)
AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 AS AMENDED.
genedrive plc
("genedrive" or the "Company")
Genedrive successful in PHE National Framework Agreement for
Diagnostics Goods and Services
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, announces it has been successful with its tender into
Public Health England ("PHE") under Lot 1 of the National
Microbiology Framework (Diagnostic Goods and Services).
The PHE tender was opened in November 2020 and sought to appoint
suppliers to a multi-lot national microbiology framework agreement
relating to the supply of Diagnostics Goods and Services and
covering Clinical Laboratory Diagnostic Testing Services.
The award of a framework contract is not exclusive to the
Company, nor a guarantee of orders, however it does allow
participating authorities to issue call-off orders for products in
the future. All of genedrive's currently available and CE marked
products fall within the framework agreement: Genedrive(R) 96
SARS-CoV-2 Kit, Genedrive(R) HCV ID Kit, Genedrive(R) MT-RNR1 ID
Kit
David Budd, CEO of genedrive plc, said: "We are very pleased to
have received notice of this contract award decision and look
forward to the opportunity to engage with PHE and relevant
authorities on future potential contracts. This is an early
notification of the decision and we will update shareholders when
we have more information on what this contract may mean for orders
and revenues".
For further details please contact:
genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler:
CFO
Peel Hunt LLP (Nominated Adviser
and Joint Broker) +44 (0)20 7418 8900
James Steel / Victoria Erskine
finnCap (Joint Broker) +44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice
Lane
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Company has assays on market for the detection of
HCV, certain military biological targets, and has tests in
development for tuberculosis (mTB). The Company recently released a
high throughput SARS-CoV-2 assay and has in development a
Genedrive(R) Point of Care version of the assay, both based on
Genedrive(R) chemistry.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRBRGDSRXBDGBI
(END) Dow Jones Newswires
April 19, 2021 02:00 ET (06:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2023 to Apr 2024